Effects of avatrombopag: A Synthesis of Findings from 28 Studies

  1. Home
  2. Effects of avatrombopag
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of avatrombopag: A Synthesis of Findings from 28 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of avatrombopag: A Synthesis of Findings from 28 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Avatrombopag is an oral medication that stimulates platelet production and has been studied for its effectiveness in treating various types of thrombocytopenia. Studies have shown its potential benefits in treating thrombocytopenia related to chronic liver disease, immune thrombocytopenia, and chemotherapy-induced thrombocytopenia.

For example, in patients with chronic liver disease, avatrombopag has been shown to increase platelet count and reduce the risk of bleeding associated with invasive procedures. 16

Avatrombopag has also demonstrated efficacy in patients with immune thrombocytopenia, reducing bleeding risk and increasing platelet count. 10

Moreover, research suggests avatrombopag may be effective in treating chemotherapy-induced thrombocytopenia, a common complication of cancer treatment. 20

Benefits and Risks

Benefit Summary

Avatrombopag can be a beneficial treatment option for patients with thrombocytopenia due to its ability to increase platelet count and reduce the risk of bleeding. 16 10 20 As an oral medication, it offers convenience for patients. Furthermore, avatrombopag has the potential to minimize the need for platelet transfusions. 16

Risk Summary

Potential risks associated with avatrombopag use include side effects like headache and fatigue. 10 In some cases, a significant increase in platelet count can elevate the risk of thrombosis. 24

Comparison Between Studies

Commonalities Among Studies

Multiple studies have consistently demonstrated the ability of avatrombopag to increase platelet count. 16 10 20

Differences Between Studies

The effectiveness of avatrombopag may vary depending on the specific condition and individual patient. For instance, in patients with chronic liver disease, avatrombopag has been shown to reduce the risk of bleeding associated with invasive procedures. 16 On the other hand, in patients with immune thrombocytopenia, avatrombopag has been found to decrease the need for platelet transfusions. 10

Consistency and Contradictions of Results

Multiple studies have demonstrated the effectiveness of avatrombopag in increasing platelet count. While its effectiveness may vary depending on the condition and patient, the findings show overall consistency. 16 10 20 However, further research is needed to understand the precise mechanisms and nuances of how avatrombopag impacts thrombocytopenia treatment.

Points to Consider for Real-World Applications

While avatrombopag shows promise in increasing platelet count, it's not a guaranteed solution for all patients with thrombocytopenia. Moreover, potential side effects exist. Therefore, it's crucial to follow a doctor's guidance when using avatrombopag. 16 10 20

Limitations of Current Research

Research on avatrombopag is still ongoing, and additional studies are needed to fully understand its long-term effects and safety profile. Furthermore, avatrombopag may not be effective for all individuals with thrombocytopenia, and its effectiveness may vary among patients. 16 10 20

Future Research Directions

Future research on avatrombopag should focus on assessing its long-term effects and safety. Further investigation is also needed to identify patient characteristics that predict the effectiveness of avatrombopag as a treatment. Moreover, research is required to determine optimal dosages and administration methods for avatrombopag. 16 10 20

Conclusion

Avatrombopag is a promising drug with potential benefits for treating various forms of thrombocytopenia. However, it's crucial to remember that it's not a one-size-fits-all solution, and potential risks exist. It's essential to consult with a doctor and follow their guidance when considering avatrombopag treatment. 16 10 20 Continued research on avatrombopag is expected to lead to advancements in its use, potentially resulting in safer and more effective treatment options for patients with thrombocytopenia.

Literature analysis of 28 papers
Positive Content
27
Neutral Content
0
Negative Content
1
Article Type
7
1
1
9
27
1.

Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies.

Author: KuterDavid J, AllenLee F

Thrombocytopenia treatment

Avatrombopag is a new medication that can increase platelet counts in patients with chronic liver disease who need invasive procedures. In two Phase 1 studies, avatrombopag was safe and well-tolerated in healthy adults. Platelet counts increased significantly with doses of 20 mg daily after 13-16 days.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

4.

Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure.

Author: TerraultNorah A, HassaneinTarek, HowellCharles D, JoshiShobha, LakeJohn, SherLinda, VargasHugo, McIntoshJoe, TangShande, JenkinsTim M

Increased platelet counts
Fatigue
Headache
Nausea
Portal vein thrombosis

A phase II, multicenter study investigated the efficacy and safety of avatrombopag in patients with thrombocytopenia secondary to cirrhosis undergoing elective invasive procedures. The study found that avatrombopag was generally well-tolerated and increased platelet counts, but one patient developed portal vein thrombosis.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists.

Author: Al-SamkariHanny

Management of CIT
Reduced bleeding events

Chemotherapy-induced thrombocytopenia (CIT) is a common complication of cancer treatment. This review discusses the use of thrombopoietin receptor agonists (TPO-RAs) for managing CIT. TPO-RAs have shown promise in clinical trials and offer a safe and effective option for preventing and managing CIT.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures.

Author: GalloPaolo, TerraccianiFrancesca, Di PasqualeGiulia, EspositoMatteo, PicardiAntonio, Vespasiani-GentilucciUmberto

TPO agonists
Thrombocytopenia treatment
Bleeding risk
Chronic liver disease

TPO-receptor agonists, such as avatrombopag and lusutrombopag, are promising new drugs for treating thrombocytopenia in patients with chronic liver disease. They can increase platelet production, potentially reducing the need for platelet transfusions.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

10.

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.

Author: JurczakWojciech, ChojnowskiKrzysztof, MayerJiří, KrawczykKatarzyna, JamiesonBrian D, TianWei, AllenLee F

ITP treatment
Contusion
Headache

Avatrombopag was shown to be effective in treating chronic immune thrombocytopenia (ITP) in adults with platelet counts less than 30 × 10^9/L. The medication was superior to placebo in increasing platelet counts and reducing the need for other medications. The most common side effects were headache and contusion.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

12.

Fostamatinib or Thrombopoietic Receptor Agonists for the Treatment of Chronic Immune Thrombocytopenia in Adult Patients: A Real-World Assessment of Safety, Effectiveness and Cost.

Author: DranitsarisGeorge, PeevyhouseAaron, WoodTiffany, KreychmanYuliya, NeuhalfenHeather, MoeziMehdi

ITP treatment

This real-world study compared the safety, effectiveness, and cost of fostamatinib with thrombopoietic agents (TPOs) for the treatment of chronic immune thrombocytopenia purpura (ITP) in adults.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

13.

Efficacy and Incidence of Treatment-Related Adverse Events of Thrombopoietin Receptor Agonists in Adults with Immune Thrombocytopenia: A Systematic Review and Network Meta-Analysis of Randomized Controlled Study.

Author: LiuYin, ZhangHan-Xi, SuJuan, GengQing-Chao, LinXin, FengChen-Xi

Adult ITP treatment
Avatrombopag efficacy
Platelet response rate
TRAEs

Avatrombopag appears to be the optimal choice as a second-line therapy for adult immune thrombocytopenia (ITP). This network meta-analysis of 14 randomized controlled trials showed that avatrombopag had the highest platelet response rate and the least risk of treatment-related adverse events.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

14.

Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States.

Author: DieterichDouglas T, BernsteinDavid, FlammSteven, PockrosPaul J, ReauNancy

Thrombocytopenia treatment
Bleeding risk

This study discusses the management of thrombocytopenia, a common hematological abnormality in patients with chronic liver disease. The authors highlight the potential risks of bleeding during or after invasive procedures and the use of novel agents that target the thrombopoietin pathway as alternatives to platelet transfusion.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

16.

Avatrombopag maleate for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease.

Author: Al-SamkariH

Thrombocytopenia treatment

Avatrombopag is a new drug that stimulates the production of platelets. It is approved by the FDA for treating periprocedural thrombocytopenia in patients with chronic liver disease. It is also being studied for other uses, such as treating immune thrombocytopenia and chemotherapy-induced thrombocytopenia.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

17.

The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.

Author: KuterDavid J

Favorable pharmacological profile
Treatment options

Avatrombopag, a TPO-R agonist, exhibits a favorable pharmacological profile with no drug-drug interactions, food interactions, or potential for chelation, making it a promising treatment option for thrombocytopenia in various conditions.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

18.

European Delphi panel to build consensus on tapering and discontinuing thrombopoietin receptor agonists in immune thrombocytopenia.

Author: BarlassinaAdele, González-LópezTomás José, CooperNichola, ZajaFrancesco

ITP management consensus
TPO-RA tapering strategies

This study aimed to establish a pan-European consensus on tapering and discontinuing thrombopoietin receptor agonists (TPO-RAs) in patients with immune thrombocytopenia (ITP). The study found that there is a lack of consensus on many aspects of this practice, highlighting the need for further research and development of clinical guidelines.

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

19.

Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease.

Author: XuHongming, CaiRong

Bleeding reduction
Platelet increase

Avatrombopag is a new oral thrombopoietin receptor agonist that is effective in treating thrombocytopenia in patients with chronic liver disease.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

20.

Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial.

Author: Al-SamkariHanny, Kolb-SieleckiJaroslaw, SafinaSufiia Z, XueXiaoqiang, JamiesonBrian D

Thrombocytopenia treatment

This study evaluated avatrombopag, a thrombopoietin receptor agonist that increases platelet counts, in patients with non-haematological cancer and platelet counts lower than 50&#8200;&#215;10<sup>9</sup> cells per L. Avatrombopag is a potential treatment for chemotherapy-induced thrombocytopenia.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

21.

A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia.

Author: BusselJames B, KuterDavid J, AledortLouis M, KesslerCraig M, CukerAdam, PendergrassKelly B, TangShande, McIntoshJoe

ITP treatment
Epistaxis
Fatigue
Headache

This 28-day phase 2 study investigated the efficacy and safety of avatrombopag, a nonpeptide thrombopoietin-receptor agonist, in patients with immune thrombocytopenia (ITP). The study found that avatrombopag was effective in increasing platelet counts and was generally well tolerated, with similar response rates and side effects to other TPO-RAs.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

23.

Avatrombopag for the treatment of immune thrombocytopenia.

Author: Długosz-DaneckaMonika, ZdziarskaJoanna, JurczakWojciech

ITP treatment
Platelet count increase

Avatrombopag, a new drug used to treat thrombocytopenia, has a good safety profile and is effective in increasing platelet counts.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

26.

Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies.

Author: KuterDavid J, AllenLee F

Thrombocytopenia treatment

Avatrombopag is a new medication that can increase platelet counts in patients with chronic liver disease who need invasive procedures. In two Phase 1 studies, avatrombopag was safe and well-tolerated in healthy adults. Platelet counts increased significantly with doses of 20 mg daily after 13-16 days.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

27.

Avatrombopag Effectively Maintained Platelet Counts in a Patient with Immune Thrombocytopenia Who Was Intolerant to Tyrosine Kinase Inhibitor Therapy.

Author: MaitlandHillary S

Platelet recovery
Reduced adverse events
Diarrhea

This case report describes a 61-year-old woman with chronic refractory immune thrombocytopenia successfully treated with fostamatinib, but who experienced diarrhea as a side effect. The study demonstrates the effectiveness of combining fostamatinib with avatrombopag to mitigate adverse events and maintain high platelet counts, suggesting a potential alternative treatment approach for immune thrombocytopenia.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

28.

Avatrombopag: First Global Approval.

Author: ShirleyMatt

Thrombocytopenia treatment

Avatrombopag is an orally bioavailable thrombopoietin receptor agonist approved for treating thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled for a procedure. This article summarizes the milestones in the development of avatrombopag and its potential applications in other thrombocytopenic disorders.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.